Poster summary for PKD 2021 | RGLS Message Board Posts

Regulus Therapeutics Inc.

  RGLS website

RGLS   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  719 of 746  at  6/24/2021 11:38:00 AM  by


Poster summary for PKD 2021

 The poster will be presented at 3:00 PM Friday, I think.

Preclinical Evaluation and Results from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with ADPKD

Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in either PKD1 or PKD2 genes, which results in kidney cyst formation. Here we report the evaluation of RGLS4326, a novel investigational drug identified to inhibit a target called miR-17, and to slow down kidney cyst growth. We have shown that miR-17 is overproduced in kidneys of ADPKD patients and causes decreased levels of PC1 and PC2 (proteins encoded by PKD1 and PKD2). In studies in animals with PKD, RGLS4326 increased levels of PC1 and PC2, reduced kidney injury marker uNGAL, and inhibited kidney cyst growth. In an ongoing Phase 1b study in patients with ADPKD, four doses of subcutaneous (s.c.) injections every other week of RGLS4326 in the first cohort was well tolerated and showed increases in urinary PC1 and PC2 levels. The study is continuing to enroll ADPKD patients in additional cohorts to evaluate different doses of RGLS4326.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0  
   Views: 0 []
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
720 Re: Poster summary for PKD 2021 - Link to poster Steve_382 3 6/25/2021 3:53:13 PM

Financial Market Data provided by